-+ 0.00%
-+ 0.00%
-+ 0.00%

Genprex Presents Preclinical Data Showing TROP2 Levels May Help Predict Which Tumors Respond To Its Candidate Reqorsa

Benzinga·11/19/2026 12:15:31
Listen to the news

New preclinical data identifying low TROP2 expression as a potential predictive biomarker of primary resistance to its lead drug candidate, Reqorsa® (quaratusugene ozeplasmid), a gene therapy product, in non-small cell lung cancer (NSCLC). The findings were presented in a poster titled "TROP2 Predicts Response to TUSC2 Gene Therapy and Its Modulation Sensitizes Non-Small Cell Lung Cancer to Treatment" at the 2026 EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place November 18-20, 2026 in Barcelona, Spain.

The TUSC2 tumor suppressor protein expression is downregulated or absent in more than 80% of NSCLC cases and nearly all small cell lung cancers. Previous studies have shown that REQORSA has antitumor activity, including in models resistant to targeted therapies and in immunotherapy-resistant KRAS/LKB1-mutant NSCLC. REQORSA's effects are mediated by inhibiting MAPK and mTOR signaling, inducing cell-cycle arrest and apoptosis, and activating antitumor immune responses.

Key findings from the research include:

  • Low TROP2 expression associated with resistance: Approximately 50% of 10 NSCLC cell lines and 50% of 12 patient derived organoid models evaluated showed primary resistance to TUSC2 gene delivery. Protein-expression analyses consistently identified low TROP2 expression as a marker associated with resistance across multiple preclinical models.
  • Supporting clinical evidence: Analysis of pretreatment tumor biopsies from patients enrolled in a TUSC2 gene therapy clinical trial supported the association between TROP2 expression and treatment response.
  • TROP2 modulation influenced treatment sensitivity: Introducing TROP2 into TROP2-low NSCLC cells (H460 and H1299) significantly increased TUSC2-induced apoptosis, to levels similar to cells that naturally express high TROP2. Conversely, knocking down or knocking out TROP2 in TROP2-high cells (H358 and H322) using shRNA or CRISPR/Cas9 also significantly increased sensitivity to TUSC2 gene therapy.

Collectively, the findings identify TROP2 as a potential predictive biomarker for response to REQORSA and suggest that modulating TROP2 signaling may be a novel strategy to enhance the therapeutic efficacy of REQORSA in NSCLC. While these findings provide preclinical and supportive clinical evidence, additional research and prospective clinical evaluation will be required to establish TROP2's predictive utility in patients receiving REQORSA.